Table 1.

Clinicopathologic characteristics of patients with ovarian cancer included in this study

IDTumor typeBRCA statusDate primary diagnosisStage primary diseaseNeoadjuvant chemotherapyCycles platinum-based chemotherapy (n)Date disease progression/distant relapsePrimary refractory/resistant diseaseSecondary refractory/resistant diseaseDate blood drawDisease location at blood drawTime follow-up (years)Follow-upcfDNA (ng) per mL plasmaFraction ctDNA in cfDNA (%)
OCT1HGSOCBRCA1February 2008Stage IIINo6May 2010ResistantAugust 2013Intra8DOD27.9NA
OCT2HGSOCBRCA2February 2011Stage IIINo6May 2012RefractoryAugust 2013Intra and extra3DOD20.432.74
OCT3HGSOCBRCA2July 2010Stage IVNo6July 2012ResistantAugust 2013NED6AWD16.30
OCT5HGSOCBRCA1July 2012Stage IIINo6May 2013ResistantRefractorySeptember 2013NED4AWD12.0NA
OCT6HGSOCBRCA1May 2010Stage IVNo6July 2011RefractorySeptember 2013Intra4DOD7.62.49
OCT7HGSOCBRCA2May 2008Stage IIINo6June 2009RefractorySeptember 2013Intra8DOD6.20.32
OCT8HGSOCBRCA2July 2006Stage IVNo6July 2007RefractorySeptember 2013Intra and extra8DOD5.91.60
OCT9HGSOCBRCA1April 2011Stage IVNo6August 2012RefractoryOctober 2013Intra and extra3DOD12.00.08
OCT10HGSOCBRCA1January 2012Stage IVYes (4 cycles)3January 2013ResistantNoOctober 2013Intra4NED4.80.26
OCT11HGSOCBRCA2June 2006Stage IVNo7October 2008ResistantDecember 2013Intra and extra9DOD11.610.30
OCT12HGSOCBRCA2June 2007Stage IIINo6July 2010RefractoryJune 2014Intra8DOD10.80.05
OCT13HGSOCBRCA1December 2007Stage IINo6January 2011RefractoryJune 2014Intra7DOD5.50.14
OCT14HGSOCBRCA1January 2012Stage IIINo6June 2013ResistantJune 2014Intra4DOD24.30.08
OCT15HGSOCBRCA1August 2012Stage IVYes (3 cycles)3October 2013ResistantAugust 2014Intra3DOD32.40.31
OCT17HGSOCBRCA1August 2008Stage IVNo6January 2010RefractorySeptember 2014Intra and extra8DOD17.44.48
OCT18HGSOCBRCA2May 1996Stage IINo6December 2004ResistantOctober 2014Intra19DOD11.45.32
OCT19HGSOCBRCA1September 2010Stage IIINo6December 2011RefractoryDecember 2014Intra4DOD300.61
OCT20HGSOCBRCA1June 2008Stage IIINo6February 2010RefractoryDecember 2014Intra7DOD32.40.12
OCT21Endometrioid (serous components)BRCA1June 2008Stage IIINo14December 2010RefractoryMarch 2015Intra and extra7DOD150.24
  • Abbreviations: AWD, alive with disease; DOD, dead of disease; HGSOC, high-grade serous ovarian cancer; intra, intra-abdominal; intra and extra, intra- and extra-abdominal; MAF, mutant allele fraction; NA, not assessable due to the lack of a somatic mutation bioinformatically inferred as clonal in the tumor sample; hence, the fraction of ctDNA in cfDNA could not be calculated; NED, no evidence of disease; ND, not detectable.